238120 — Aligned Genetics Balance Sheet
0.000.00%
- KR₩45bn
- KR₩30bn
- KR₩16bn
- 65
- 55
- 64
- 69
Annual balance sheet for Aligned Genetics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12,139 | 13,137 | 13,696 | 14,927 | 18,019 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,519 | 2,563 | 1,469 | 2,723 | 2,951 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 15,942 | 18,386 | 19,552 | 21,603 | 25,567 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,673 | 5,776 | 7,285 | 8,035 | 7,770 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 25,481 | 34,469 | 36,901 | 40,932 | 44,275 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,219 | 1,417 | 1,333 | 5,238 | 1,896 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 4,017 | 7,477 | 8,052 | 9,620 | 8,781 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 21,464 | 26,992 | 28,850 | 31,311 | 35,494 |
Total Liabilities & Shareholders' Equity | 25,481 | 34,469 | 36,901 | 40,932 | 44,275 |
Total Common Shares Outstanding |